Publications by authors named "Marta Gaggiola"

Claim this Profile
C
Case Report: Asymptomatic macular edema in ozanimod.
Valentina Annamaria Mauceri, Tommaso Torresin, Elisa Basili, Marta Gaggiola, Francesca Rinaldi

Front Ophthalmol (Lausanne)· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The immunological bases of alemtuzumab as induction-therapy in pediatric-onset multiple sclerosis.
Marco Puthenparampil, Marta Gaggiola, Francesca Rinaldi, M Nosadini, S Sartori

Front Immunol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relapsing tumefactive demyelination lesions: A unique, distinct inflammatory brain pathology.
Paola Perini, Marta Gaggiola, Francesca Rinaldi, Paolo Gallo, Marco Puthenparampil

Mult Scler· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of natalizumab's effects on SDMT between pediatric-onset and adult-onset multiple sclerosis patients.
Marco Puthenparampil, Graziana Scialpi, Marta Gaggiola, Giovanni Zanotelli, Alessandro Miscioscia

Front Neurol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High NEDA and No PIRA in Natalizumab-Treated Patients With Pediatric-Onset Multiple Sclerosis.
Marco Puthenparampil, Marta Gaggiola, Marta Ponzano, Giovanni Zanotelli, Alessandro Miscioscia

Neurol Neuroimmunol Neuroinflamm· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alemtuzumab following natalizumab is more effective in adult-onset than paediatric-onset multiple sclerosis.
Marco Puthenparampil, Marta Gaggiola, Alessandro Miscioscia, Valentina Annamaria Mauceri, Federica De Napoli

Ther Adv Neurol Disord· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis